Biogen's stock struggles are linked to the slow launch of Al...

Biogen's stock struggles are linked to the slow launch of Alzheimer's drug Leqembi, facing challenges like limited capacity at infusion centers and long neurologist wait times. A convenient under-the-skin injection version could outperform Eli Lilly's potential rival, donanemab.